CARISMA THERAPEUTICS INC (CARM)
US14216R1014 - Common Stock
We assign a fundamental rating of 1 out of 10 to CARM. CARM was compared to 576 industry peers in the Biotechnology industry. Both the profitability and financial health of CARM have multiple concerns. CARM does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year CARM has reported negative net income.
CARM had a negative operating cash flow in the past year.
In the past 5 years CARM always reported negative net income.
CARM had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
With a Return On Assets value of -110.06%, CARM is not doing good in the industry: 80.10% of the companies in the same industry are doing better.
CARM has a worse Return On Equity (-745.44%) than 81.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -110.06% | ||
| ROE | -745.44% | ||
| ROIC | N/A |
ROA(3y)-35.89%
ROA(5y)-44%
ROE(3y)-113.4%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CARM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CARM does not have a ROIC to compare to the WACC, probably because it is not profitable.
CARM has more shares outstanding than it did 1 year ago.
CARM has more shares outstanding than it did 5 years ago.
CARM has a worse debt/assets ratio than last year.
2.2 Solvency
CARM has an Altman-Z score of -7.29. This is a bad value and indicates that CARM is not financially healthy and even has some risk of bankruptcy.
CARM has a Altman-Z score of -7.29. This is in the lower half of the industry: CARM underperforms 71.38% of its industry peers.
CARM has a Debt/Equity ratio of 0.08. This is a healthy value indicating a solid balance between debt and equity.
CARM has a worse Debt to Equity ratio (0.08) than 63.53% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.08 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -7.29 |
ROIC/WACCN/A
WACC10.9%
2.3 Liquidity
CARM has a Current Ratio of 4.64. This indicates that CARM is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 4.64, CARM perfoms like the industry average, outperforming 48.69% of the companies in the same industry.
CARM has a Quick Ratio of 4.64. This indicates that CARM is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of CARM (4.64) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.64 | ||
| Quick Ratio | 4.64 |
3. Growth
3.1 Past
CARM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 49.11%, which is quite impressive.
The Revenue for CARM has decreased by -65.13% in the past year. This is quite bad
CARM shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.90% yearly.
EPS 1Y (TTM)49.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.17%
Revenue 1Y (TTM)-65.13%
Revenue growth 3Y9.9%
Revenue growth 5YN/A
Sales Q2Q%4.75%
3.2 Future
The Earnings Per Share is expected to grow by 7.54% on average over the next years.
CARM is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -2.06% yearly.
EPS Next Y62.89%
EPS Next 2Y27.83%
EPS Next 3Y16.82%
EPS Next 5Y7.54%
Revenue Next Year14.65%
Revenue Next 2Y-15.8%
Revenue Next 3Y-25.99%
Revenue Next 5Y-2.06%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
CARM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CARM. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as CARM's earnings are expected to grow with 16.82% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.83%
EPS Next 3Y16.82%
5. Dividend
5.1 Amount
CARM does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CARISMA THERAPEUTICS INC
NASDAQ:CARM (7/3/2024, 6:57:42 PM)
After market: 1.37 -0.02 (-1.44%)1.39
-0.05 (-3.47%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap57.74M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -110.06% | ||
| ROE | -745.44% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.2
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.08 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.64 | ||
| Quick Ratio | 4.64 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)49.11%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y62.89%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-65.13%
Revenue growth 3Y9.9%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y